Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart pump timing put to the test in deadly heart attack shock

NCT ID NCT07817472

Disease control Sponsor: Chonnam National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 14, 2026 · Last updated Sep 15, 2026 · Updated 1 time

Summary

Researchers compare two timing strategies for the Impella CP heart pump in people who have a heart attack and develop cardiogenic shock, a dangerous state where the heart cannot pump enough blood. One group receives the pump before the artery-opening procedure called PCI, while the other receives it only if needed during or after PCI. The trial measures death or persistent shock within 48 hours to see which approach works better.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Impella CP, a tiny heart pump inserted through a blood vessel to help the heart pump blood
What this could lead to
If it works, this could show the best moment to start mechanical heart support during a heart attack, helping more people survive cardiogenic shock.
What could go wrong
The trial is small and single-center, so its results may not apply everywhere. Inserting a heart pump before PCI carries bleeding, vessel damage, and infection risks, and the timing strategy may not improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 126 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Jul 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥19 years old * Acute myocardial infarction with culprit lesion requiring urgent percutaneous coronary intervention * Cardiogenic shock before culprit lesion percutaneous coronary intervention * Left ventricular ejection fraction ≤40% * Patients with persistent signs of shock despite medical therapy who are scheduled to undergo Impella CP insertion * Shock onset to randomization ≤12 hours Exclusion Criteria: * Non-acute myocardial infarction-related shock * No clear culprit lesion * Mechanical complication of myocardial infarction * Predominant right ventricular or biventricular shock * Ongoing cardiopulmonary resuscitation at the time of screening * Refractory ventricular arrhythmia * Unwitnessed cardiac arrest without bystander cardiopulmonary resuscitation * Cardiopulmonary resuscitation duration \>45 minutes * Glasgow Coma Scale \<8 after return of spontaneous circulation * Contraindication to Impella CP use * Prior mechanical circulatory support before randomization * Active major bleeding or inability to receive anticoagulation or antiplatelet therapy required for percutaneous coronary intervention and Impella CP support * Life expectancy \<1 year

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiogenic shock are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cardiogenic shock myocardial infarction Non-ST Elevated Myocardial Infarction Shock, Cardiogenic ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiogenic shock Myocardial infarction (MI) Non-ST-segment elevation myocardial infarction (nstemi) ST-segment elevation myocardial infarction (stemi)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Chonnam National University Hospital

    Gwangju, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.